Correct Answer: C. Colchicine
Colchicine is the classic drug known to inhibit neutrophil recruitment, making it the correct answer. Colchicine binds to tubulin dimers and prevents their polymerization into microtubules, thereby disrupting the cytoskeletal machinery that neutrophils depend on for directed migration (chemotaxis), adhesion to endothelial surfaces, and extravasation into inflamed tissues. Without intact microtubule networks, neutrophils cannot effectively respond to chemotactic signals such as IL-8, C5a, and leukotriene B4 (LTB4), and their recruitment to sites of inflammation is markedly impaired.
This mechanism is clinically exploited in acute gout, where monosodium urate crystals trigger a massive neutrophil influx into the synovial space. Colchicine, by blocking neutrophil recruitment and subsequent degranulation (release of lysosomal enzymes and reactive oxygen species), rapidly dampens the inflammatory cascade. It also inhibits NLRP3 inflammasome activation and IL-1β release, further reducing the pro-inflammatory milieu that drives neutrophil chemotaxis. Colchicine is also used in familial Mediterranean fever, pericarditis, and Behçet's disease — all conditions where neutrophil-mediated inflammation is central.
Why other options are wrong
- A. Montelukast — A cysteinyl leukotriene receptor (CysLT1) antagonist used in asthma and allergic rhinitis. It primarily reduces eosinophil recruitment and bronchoconstriction. It does not specifically inhibit neutrophil recruitment and has no role in neutrophil-driven inflammatory conditions like gout.
- B. Febuxostat — A selective xanthine oxidase inhibitor used for urate-lowering in chronic gout. Its primary mechanism is reducing uric acid synthesis. While some anti-inflammatory effects have been described in research settings, febuxostat is not the established pharmacological agent recognized for inhibiting neutrophil recruitment. It is not used acutely for this purpose.
- D. Sodium cromolyn — A mast cell stabilizer that prevents degranulation and release of histamine and other mediators in allergic conditions. It acts on mast cells, not neutrophils, and does not inhibit neutrophil recruitment. It is used in allergic asthma and rhinitis, not in neutrophil-mediated inflammation.